Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 200 IN PLASTIC CONTAINER versus ORAGRAFIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 200 IN PLASTIC CONTAINER versus ORAGRAFIN SODIUM.
IOPAMIDOL-200 IN PLASTIC CONTAINER vs ORAGRAFIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing vascular and tissue contrast during imaging procedures.
Oragrafin Sodium is an oral cholecystographic contrast agent containing sodium ipodate. It is absorbed orally, excreted by the liver into bile, and concentrates in the gallbladder, allowing radiographic visualization. The iodine atoms in the molecule absorb X-rays, providing contrast. It also inhibits thyroid hormone synthesis by blocking iodine organification and may be used in amiodarone-induced thyrotoxicosis.
Intravascular administration: 1-2 mL/kg (200 mg I/mL) intravenously, up to a maximum of 150 mL per diagnostic procedure. Intraarterial administration: varies by procedure; typical 5-60 mL per injection.
Oral: 50-60 mL of a 10% solution (5-6 g sodium iopodate) as a single dose 10-12 hours before cholecystography. Repeat if needed: 50 mL (5 g) the next evening. Intravenous: Not applicable (oral agent).
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 60-90 minutes in patients with normal renal function (creatinine clearance > 90 mL/min), reflecting rapid renal clearance of this water-soluble contrast agent.
Primarily renal (99% unchanged in urine within 24 hours). Biliary/fecal excretion <1%.
Primarily renal (hepatic/biliary/fecal: minimal). Approximately 80-90% of the absorbed dose is excreted unchanged in urine via glomerular filtration; <10% eliminated in feces via biliary excretion.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent